A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

NCT02572687 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma

Interventions

DRUG: Ramucirumab
DRUG: MEDI4736

Sponsor

Eli Lilly and Company

Collaborators

[object Object]